Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEversept Partners, LP
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Eversept Partners, LP ownership in VRTX / Vertex Pharmaceuticals Incorporated

On November 8, 2023 - Eversept Partners, LP filed a 13F-HR/A form disclosing ownership of 0 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $0 USD as of March 31, 2022. The entity filed a previous 13F-HR/A on November 8, 2023 disclosing 54,500 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Eversept Partners, LP has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 90,000 of underlying shares valued at $40,188,600 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2023-11-08 2022-03-31 13F/A-1 VERTEX PHARMACEUTICALS CALL 92532F900 0 -94,100 -100.00 0 -100.00
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS CALL 92532F900 0 -941 0
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS CALL 92532F900 941 -792 5,971 0.4395
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS CALL 92532F900 1,733 -52,767 2,743 0.2054
2023-11-08 2021-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 54,500 53,900 8,983.33 10,989 75.44 0.7324
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS CALL 92532F900 1,733 -58,267 9,192 0.7208
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 54,500 53,900 10,989 0.8617
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS CALL 92532F900 600 600 6,263 0.4960
2023-11-08 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 -73,009 -100.00 0 -100.00
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -73,009 0
2023-11-08 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 73,009 22,100 43.41 15,985 85.33 2.8229
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 73,009 22,100 15,985 3.0965
2023-11-08 2019-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 50,909 -6,940 -12.00 8,625 -18.69 2.6756
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 50,909 -6,940 8,625 2.6927
2023-11-08 2019-06-30 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 57,849 19,620 51.32 10,608 50.85 2.9706
2019-10-30 2019-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 57,849 19,620 10,608 2.9940
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 57,849 19,620 10,608
2023-11-08 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 38,229 1,737 4.76 7,032 16.29 2.0514
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 38,229 1,737 7,032 2.0755
2023-11-08 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 36,492 -11,600 -24.12 6,047 -34.76 3.2745
2019-02-13 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,492 -11,600 6,047 3.3465
2023-11-08 2018-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 48,092 13,270 38.11 9,269 56.62 4.0681
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 48,092 13,270 9,269 4.4616
2023-11-08 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 34,822 -10,000 -22.31 5,918 -18.99 2.7069
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,822 -10,000 5,918 2.8230
2023-11-08 2018-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 44,822 -13,300 -22.88 7,305 -16.13 3.3929
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 44,822 -13,300 7,305 3.4963
2023-11-08 2017-12-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 58,122 58,122 8,710 5.0117
2018-02-13 2017-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 58,122 58,122 8,710 5.6589
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM Call 90,000 -4.36 40,189 94.48 n/a n/a n/a
2023-11-08 2022-03-31 13F/A VERTEX PHARMACEUTICALS CALL 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-08 2022-03-31 13F/A VERTEX PHARMACEUTICALS COM Call 0 0 n/a n/a n/a
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS CALL 0 0 n/a n/a n/a
2023-11-08 2021-12-31 13F/A VERTEX PHARMACEUTICALS COM Call 94,100 -45.70 20,664 -34.26 n/a n/a n/a
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS CALL 941 5,971 n/a n/a n/a
2023-11-08 2021-09-30 13F/A VERTEX PHARMACEUTICALS COM Call 173,300 0.00 31,435 -10.04 n/a n/a n/a
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS CALL 1,733 2,743 n/a n/a n/a
2023-11-08 2021-06-30 13F/A VERTEX PHARMACEUTICALS COM Call 173,300 188.83 34,942 171.02 n/a n/a n/a
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS CALL 1,733 9,192 n/a n/a n/a
2023-11-08 2021-03-31 13F/A VERTEX PHARMACEUTICALS COM Call 60,000 12,893 n/a n/a n/a
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS CALL 600 6,263 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.